Kyle Doherty

Articles

Pirtobrutinib Monotherapy Demonstrates Early Activity in R/R Follicular Lymphoma

December 11th 2023

Treatment with single-agent pirtobrutinib showed encouraging efficacy with a tolerable safety profile in a cohort of heavily pretreated patients with relapsed/refractory follicular lymphoma.

Golidocitinib Demonstrates Efficacy in Relapsed/Refractory PTCL

December 10th 2023

Golidocitinib displayed antitumor activity and an acceptable safety profile in patients with refractory/relapsed peripheral T-cell lymphoma, according to data from the pivotal phase 2 JACKPOT8 study.

Datopotamab Deruxtecan Prolongs PFS in HR+/HER2- Inoperable or Metastatic Breast Cancer

December 7th 2023

Datopotamab deruxtecan resulted in a statistically significant and clinically meaningful improvement in progression-free survival compared with chemotherapy among patients with previously treated, hormone receptor-positive/HER2-negative inoperable or metastatic breast cancer.

Westin Testifies to Senate Finance Committee on Cancer Drug Shortage

December 5th 2023

Shortages of several anticancer drugs continue to negatively impact clinicians’ ability to deliver the best possible care to patients.

New Developments in MPN Management Provide Additional Options for Patients

December 5th 2023

Significant progress has been made in terms of understanding myeloproliferative neoplasms and developing treatment strategies to combat them.

Neoadjuvant Chemotherapy Does Not Give Survival Benefit Over Chemoradiation in Cervical Cancer

December 3rd 2023

Neoadjuvant chemotherapy preceding surgery did not result in a significant difference in 5-year overall survival rates compared with concomitant chemoradiotherapy in patients with stage IB2 to IIB cervical carcinoma, according to findings from the phase 3 EORTC-55994 trial.

Adding Pemetrexed to Cisplatin Does Not Result in Survival Benefit Over Vinorelbine in NSCLC

December 2nd 2023

Adjuvant treatment with the chemotherapy doublet of pemetrexed and cisplatin did not lead to a significant improvement in overall survival compared with vinorelbine plus cisplatin in patients with stage II to IIIA nonsquamous non–small cell lung cancer.

Cretostimogene Grenadenorepvec Confers High CR Rate in NMIBC

December 1st 2023

Preliminary findings from the phase 3 BOND-003 trial showed that treatment with cretostimogene grenadenorepvec led to sustained and durable complete responses and a tolerable safety profile in patients with high-risk non-muscle invasive bladder cancer who are unresponsive to Bacillus Calmette-Guerin.

ADC Choices Require Discretion in HER2-Negative MBC

November 30th 2023

With multiple antibody drug conjugate options now available for patients with HER2-negative metastatic breast cancer, clinicians must consider a variety of factors when selecting and sequencing therapies.

EG12014 Gets Go Ahead in EU for HER2+ Breast and Metastatic Gastric Cancers

November 28th 2023

EG12014, a biosimilar of the anti-HER2 monoclonal antibody trastuzumab, has received a marketing authorization from the European Commission for use in the European Union for the treatment of patients with HER2-positive breast and metastatic gastric cancer; these are the same indications that trastuzumab holds in the EU.

PC14586 Targets Previously “Undruggable” p53 in Treatment of Solid Tumors

November 27th 2023

Despite previous unsuccessful attempts to target p53, investigators have continued to try to develop novel therapeutics directed at the tumor suppressor gene with the goal of restoring p53 wild-type activity.

FDA Approval Sought for Obe-Cel in Relapsed/Refractory B-ALL

November 27th 2023

A biologics license application seeking the approval of obecabtagene autoleucel for the treatment of adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia has been submitted to the FDA.

Evolving Treatment Patterns Lead to Improved Outcomes in Relapsed/Refractory MCL

November 20th 2023

Patients with relapsed/refractory mantle cell lymphoma have experienced event-free survival and overall survival benefits due to advances in second-line treatment approaches over time.

Lenalidomide Plus Rituximab Elicits Prolonged Responses in Mantle Cell Lymphoma

November 20th 2023

Initial induction therapy with the immunomodulatory agent lenalidomide plus the anti-CD20 monoclonal antibody rituximab led to prolonged, durable responses with a manageable safety profile in patients with previously untreated mantle cell lymphoma.

CAR-M Therapy CT-0508 Shows Promise in HER2-Overexpressing Recurrent/Metastatic Solid Tumors

November 19th 2023

The HER2-directed CAR-macrophage therapy CT-0508 displayed a tolerable safety profile and signs of antitumor activity in patients with a variety of solid tumors.

Allogeneic HCT Provides OS Benefit Independent of TP53 Allelic Status in MDS

November 18th 2023

Patients with myelodysplastic syndrome harboring a TP53 mutation experienced a survival benefit with allogeneic hematopoietic cell transplantation compared with non-HCT treatment regardless of TP53 allelic status.

Zanubrutinib Plus Obinutuzumab Gets EU Approval for R/R Follicular Lymphoma

November 17th 2023

The European Commission has granted marketing authorization to the combination of zanubrutinib and obinutuzumab for the treatment of adult patients with relapsed/refractory follicular lymphoma following at least 2 prior lines of systemic therapy.

Administrative Payment Tasks Could Be Causing Detrimental Effect of Treatment Delays and Nonadherence for Patients With Cancer

November 15th 2023

A possible cause of some of the cost-related delays and nonadherence to treatment that patients with cancer and cancer survivors experience could be the time and effort they are forced to spend on administrative payment tasks related to their care.

PD-L1 IHC 22C3 pharmDx Gets Green Light From FDA for Determining Pembrolizumab Eligibility in Gastric/GEJ Adenocarcinoma

November 14th 2023

The FDA has approved the PD-L1 IHC 22C3 pharmDx diagnostic tool to aid clinicians in identifying patients with gastric or gastroesophageal junction adenocarcinoma who may be eligible for treatment with the PD-1 inhibitor pembrolizumab.

NCCN Endorses Goserelin in Salivary Gland Tumors in New Head and Neck Cancers Guidelines

November 13th 2023

TerSera Therapeutics LLC announced that The National Comprehensive Cancer Network Head and Neck Cancers Panel recommended the GnRH agonist goserelin for patients with recurrent, unresectable, or metastatic salivary gland tumors who were not eligible for surgery or radiation therapy.